Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | EED | O75530 | 2/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9922003 | 0.86 | KMT2A (0.50) | MEN1KMT2AACHETAAR1HTT | |
| SCHEMBL14375354 | 0.86 | MEN1 (0.50) | MEN1KMT2ATAAR1EGFRSMN1; SMN2 | |
| SCHEMBL20249844 | 0.81 | ACHE (0.43) | MEN1KMT2AACHETAAR1SMN1; SMN2 | |
| SCHEMBL31459480 | 0.81 | ACHE (0.43) | MEN1KMT2AACHETAAR1SMN1; SMN2 | |
| SCHEMBL28122164 | 0.78 | MEN1 (0.42) | MEN1KMT2ATAAR1HTTEGFR | |
| SCHEMBL12490636 | 0.78 | TSHR (0.50) | MEN1KMT2AHTTEGFRSMN1; SMN2 | |
| SCHEMBL2032212 | 0.78 | TAAR1 (0.61) | MEN1KMT2ATAAR1HTTSMN1; SMN2 | |
| SCHEMBL3208304 | 0.77 | KDM1A (0.41) | MEN1KMT2ATAAR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9918365 | 0.77 | GABRA1 (0.43) | MEN1KMT2ATAAR1EGFRALDH1A1 | |
| SCHEMBL24594990 | 0.76 | ALDH1A1 (0.42) | MEN1KMT2ATAAR1HTTEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | MEN1 440/4885KMT2A 628/4885ACHE 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.